VANCOUVER, Feb. 13, 2012 /CNW/ - Allon Therapeutics Inc. (TSX: NPC) President and CEO Gordon McCauley will present an update of the Company's progress on Tuesday, February
14th at the 14th Annual BIO CEO & Investor Conference in New York City. During that presentation, McCauley will also discuss
the latest review of the Company's on-going pivotal trial in progressive supranuclear palsy (PSP) by the independent Data Safety Monitoring Board (DSMB) and its
recommendation to continue the study.
The DSMB recently completed its third review and unanimously recommended
continuing the trial without any change or modification to the
protocol. A DSMB is a group of clinical experts with the primary
responsibility of monitoring the safety and well-being of subjects and
to assure scientific integrity of the study. A DSMB is independent of
the company and the clinical investigators, who are blinded from the
safety and efficacy data until all treatment has been completed.
McCauley's presentation will include an update of the Company's
programs, including its fully enrolled pivotal clinical trial
evaluating its lead neuroprotective drug candidate, davunetide, as a potential treatment for PSP, a rapidly progressing and fatal
degenerative brain disease.
BIO CEO & Investor Conference is the biotechnology industry's largest
conference focused on publicly traded companies. In addition to public
presentations to biotechnology executives, institutional investors and
investment analysts, the conference facilitates private one-on-one
partnering discussions and investor meetings.
The live webcast may be viewed at 11:00 a.m. PST (2:00 p.m. EST) at http://www.veracast.com/webcasts/bio/ceoinvestor2012/83212133.cfm
The presentation will be immediately archived and available for viewing
for three months from the Company's website at www.allontherapeutics.com/corporate/news/events-and-webcasts/
Allon Therapeutics Inc. is a clinical-stage biotechnology company
focused on bringing to market innovative central nervous system
therapies. Allon's lead drug davunetide is proceeding in a fully enrolled pivotal Phase 2/3 clinical trial in
an orphan indication, progressive supranuclear palsy (PSP), under a
Special Protocol Assessment (SPA) with the U.S. Food and Drug
Administration (FDA). This pivotal trial is based upon statistically
significant human efficacy demonstrated in patients with amnestic mild
cognitive impairment (a precursor to Alzheimer's disease), cognitive
impairment associated with schizophrenia, and in positive biomarker
The Company is listed on the Toronto Stock Exchange under the trading
Forward Looking Statements
Statements contained herein, other than those which are strictly
statements of historical fact may include forward-looking information.
Such statements will typically contain words such as "believes", "may",
"plans", "will", "estimate", "continue", "anticipates", "intends",
"expects", and similar expressions. While forward-looking statements
represent management's outlook based on assumptions that management
believes are reasonable, forward-looking statements by their nature are
subject to known and unknown risks, uncertainties and other factors
that may cause the actual results, events or developments to be
materially different from any future results, events or developments
expressed or implied by them. Such factors include, among others, the
inherent uncertainty involved in scientific research and drug
development, Allon's early stage of development, lack of product
revenues, its additional capital requirements, the risks associated
with successful completion of clinical trials and the long lead-times
and high costs associated with obtaining regulatory approval to market
any product which Allon may eventually develop. Other risk factors
include the limited protections afforded by intellectual property
rights, rapid technology and product obsolescence in a highly
competitive environment and Allon's dependence on collaborative
partners and contract research organizations. These factors can be
reviewed in Allon's public filings at www.sedar.com and should be considered carefully. Readers are cautioned not to place
undue reliance on such forward-looking statements. Similarly, nothing
in this press release is meant to promote a pharmaceutical product or
make a regulated claim of efficacy.
SOURCE Allon Therapeutics Inc.
For further information:
Allon Therapeutics Inc.
Director, Investor Relations